Consistent with tumour grade, HER2+ and TNBC showed a higher proportion of cases with nuclear NDRG1 expression compared with ER+ cases, which consisted of 62% of non‐nuclear NDRG1 cases (Figure 3C) in BC and BC‐BrM patients. This evidence concerns the gene NDRG1 and breast cancer.